My research aims to identify critical knowledge gaps that link immune responses with inflammatory, infectious and metabolic diseases. I gained expertise through the pursuit of studies arising from the reductive analysis of both innate and adaptive immune responses (e.g., TLR, BAFF, Type I IFN and IL-17 signaling) in animal models. These experiences have positioned me well to lead projects aimed at defining the mechanisms underlying immunopathogenesis of various diseases.
Research areas that interest me include immunology, immunometabolism, obesity, non-alcoholic fatty liver disease (NAFLD) and preterm birth. I began my independent research career work at Cincinnati Children's in 2010. My research has been supported by the National Institutes of Health (NIH) since 2013.
The overall goal of my research program is to define the fundamental processes, mechanisms and immune pathways underlying disease pathogenesis. My ultimate objective is translational exploitation of such insights for reducing or eliminating the burden of inflammation-associated diseases.
Specifically, the focus of my laboratory is to exploit:
Further, our experimental models are supported by established and ever-developing platforms of primary human samples from individuals clinically stratified into respective disease categories.
Some of my most notable discoveries include identifying RP105 as a negative regulator of TLR4 signaling, demonstrating how IL-17 axis functions in the regulation of NAFLD progression and employing thermoneutrality as an improved, more “human-like” approach, to study inflammatory and metabolic diseases.
It is my honor to have received several awards, including:
BA: DePauw University, Greencastle, IN, 1998.
MS: Oklahoma State University, Stillwater, OK, 2000.
PhD: University of Cincinnati, Cincinnati, OH, 2005.
Post Doc: Cincinnati Children’s Hospital Medical Center, 2010
Innate immune responses; obesity; NAFLD; preterm birth; echocardiography; fetal cardiology; Cardiology Consult Service; General Cardiology Outpatient Clinic
Immunobiology, Inflammation and Tolerance
Azathioprine promotes intestinal epithelial cell differentiation into Paneth cells and alleviates ileal Crohn's disease severity. Scientific Reports. 2024; 14:12879.
Knockdown of Ketohexokinase Versus Inhibition of Its Kinase Activity Exert Divergent Effects on Fructose Metabolism. JCI insight. 2024; e184396.
BAFF neutralization impairs the autoantibody-mediated clearance of dead adipocytes and aggravates obesity-induced insulin resistance. Frontiers in Immunology. 2024; 15:1436900.
Presurgery health influences outcomes following vertical sleeve gastrectomy in adolescents. Obesity. 2024; 32:1187-1197.
Gestational and Developmental Contributors of Pediatric MASLD. Seminars in Liver Disease. 2024; 44:43-53.
Protocol for cytokine and uterine immune cell characterization in a mouse model of LPS-induced preterm birth. Star Protocols. 2023; 4:102643.
Obesity amplifies influenza virus-driven disease severity in male and female mice. Mucosal Immunology. 2023; 16:843-858.
Thermoneutral Housing Enables Studies of Vertical Transmission of Obesogenic Diet-Driven Metabolic Diseases. Nutrients. 2023; 15:4958.
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease. Cell Metabolism. 2023; 35:1852-1871.
Azathioprine promotes intestinal Paneth cell differentiation in Crohn’s disease. Zeitschrift für Gastroenterologie. 2023; 61:e410.
Senad Divanovic, PhD5/18/2021
Senad Divanovic, PhD5/17/2021
Senad Divanovic, PhD6/2/2020
Senad Divanovic, PhD7/3/2019